The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
about
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinTreatment of Adult Soft Tissue Sarcomas: An OverviewPazopanib in the treatment of soft tissue sarcomaResults of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamideOutcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine originCytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case reportDrug-induced acute kidney injury in childrenPrimary intrathoracic malignant neurogenic tumor: report of three cases and comparison with benign neurogenic tumors resected at our institution.Management of adult soft-tissue sarcoma of the extremities and trunk.Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.Trends in survival for patients with metastatic soft-tissue sarcoma.Histology-driven chemotherapy in soft tissue sarcomas.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Delayed Spinal Epidural Hematoma after En Block Spondylectomy for Vertebral Ewing's Sarcoma.Radiofrequency ablation of pulmonary metastases from sarcoma: single-center retrospective evaluation of 46 patients.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip.Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.Managing sarcoma: where have we come from and where are we going?Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.Outcome after radiofrequency ablation of sarcoma lung metastases.Value of ablation therapy in the treatment of lung metastases.Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.
P2860
Q26738346-800DA45D-AC1F-4F07-BEF5-C5EB743B5B2FQ28088685-53277568-C361-4563-BD8B-B25F4D7F8BC0Q28269229-F9B2ED2C-3426-4C67-AD60-80A5D24FE96CQ33406493-A0648A91-792B-47E7-9759-225023BD0F6AQ33523297-31EDE430-9F92-44BB-8FDE-B64E48371CD7Q34340390-9F735D53-4509-42AF-BA6C-627CD1D098E5Q34426949-7AD22F45-F3C7-41F3-B662-530F7F23D40DQ35053067-CA7253E3-2FF4-483E-B229-ABDB2C5995BBQ36125552-B2E89429-7EAD-42A3-BEEA-7A5159FDDE1BQ36564034-097B9E17-E2B1-415C-975E-02CD25962E73Q37687386-B707422F-F352-43DE-98B7-D5B891C87BBCQ37723943-43442BFF-F1C2-4328-96AB-CEAE80BCBB5FQ37800052-9C0111F5-1F17-427B-9A8A-8F779496F249Q37848174-5F845B61-F996-467B-9855-C95FD7C84F7CQ38197031-0AB2C040-7DB1-4597-AE37-D64CE4D6DCA2Q38478801-D9C5FF92-1A7E-4FA0-B1E8-CA618CEB4A92Q39172872-FDC57D5F-B0D3-4E32-A9E6-F719F668B8C8Q39233440-47D188BE-7456-40B9-94D1-F6F0F5C35346Q39570346-0789A094-604A-4CEA-BD31-3AF4EF4DFCD9Q39743562-3C673EF3-49B3-4550-AA1B-4EDC7A1A8F3EQ41501364-A561A26D-964F-48B4-B256-EE33FC1B3B10Q41988197-AD41E568-C307-4481-B9DC-690C34DE02F3Q44848568-073FA0D9-0668-4239-AACF-3330EF731E5CQ45213331-38700587-E1DC-43E6-A820-470D90BD0A13Q48200047-7E3E4838-217C-4C9A-8652-97DA84EA2CBDQ54959206-C467E55B-1CE8-4E28-A530-77B86809022B
P2860
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@ast
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@en
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@nl
type
label
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@ast
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@en
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@nl
prefLabel
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@ast
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@en
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@nl
P2093
P1433
P1476
The pharmacologic basis of ifo ...... advanced soft tissue sarcomas.
@en
P2093
Jaap Verweij
Metin Tascilar
Stefan Sleijfer
Walter J Loos
P304
P356
10.1634/THEONCOLOGIST.12-11-1351
P577
2007-11-01T00:00:00Z